Identification of by-products in support of process development of Muraglitazar.

Muraglitazar was being developed by Bristol-Myers Squibb for the treatment for type 2 diabetes and dislipidemia. Process optimization included the minimization of the by-products. This endeavor was greatly facilitated by a clear understanding of by-product identity. By-products were isolated by preparative chromatography and identified using NMR and MS. The identified structures of the by-products provided useful information about the undesired side reactions, which were then minimized or eliminated by altering the reaction conditions appropriately. Copyright © 2016 John Wiley & Sons, Ltd.